Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2573-2577

  Miyake, Hideaki ^a   Hara, Isao ^b   Eto, Hiroshi ^a  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cathepsin B; Prostate cancer; Prostate volume; Serum

Indexed keywords

CATHEPSIN B;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DENSITY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; ENZYME IMMUNOASSAY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CATHEPSIN B; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 4444332050     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Denis L and Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72: 3888, 1993.
2. Catalona WJ, Beiser JA and Smith DS: Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 158: 2162, 1997.
3. Hara I, Miyake H, Hara S, Yamanaka N, Ono Y, Eto H, Takechi Y, Arakawa S and Kamidono S: Value of serum prostate specific antigen-alpha1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int 88: 53, 2001.
4. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907, 1991.
5. Fidler IJ: Critical factors in the biology of human cancer metastasis: 28th G.H.A. Clowes Memorial Award Lecture. Cancer Res 50: 6130, 1990.
6. Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S and Nakajima M: Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79: 96, 1998.
7. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S and Kamidono S: Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39: 123, 1999.
8. Cherry JP, Mordente JA, Chapman JR, Choudhury MS, Tazaki H, Mallouh C and Konno S: Analysis of cathepsin D forms and their clinical implications in human prostate cancer. J Urol 160: 2223, 1998.
9. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Janicke F and Graeff H: Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Res 1: 741, 1995.
10. Frohlich E, Schaumbrug-Lever S and Klessen C: Immunocytochemical and immunoelectron microscopic demonstration of cathepsin B in human malignant melanoma. Br J Dermatol 132: 867, 1995.
11. Krepela E, Kasafirek E, Novak K and Viklicky J: Increased cathepsin B activity in human lung tumors. Neoplasma 37: 61, 1990.
12. Ledakis P, Tester WT, Rosenberg N, Romero-Fischmann D, Daskal I and Lah TT: Cathepsins D, B, and L in malignant human lung tissue. Clin Cancer Res 2: 561, 1996.
13. Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N and Vrhovec I: Cathepsin B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3: 1815, 1997.
14. Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW and Brunner N: Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 4: 1511, 1998.
15. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T and Terao T: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610, 1992.
16. Krueger S, Haeckel C, Buehling F and Roessner A: Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res 59: 6010, 1999.
17. Szpaderska AM and Frankfater A: An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61: 3493, 2001.
18. Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M and Sloane BF: Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 26: 171, 1995.
19. Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G, Schnorr D and Loening SA: Cathepsin B, H, L and cysteine protease inhibitors in malignant prostate cancer cell lines, primary cultured prostatic cells and prostatic tissue. Eur J Cancer 35: 138, 1999.
20. Fernandez PL, Farre X, Nadal A, Fernandez E, Peiro N, Sloane BF, Shi GP, Chapman HA, Campo E and Cardesa A: Expression of cathepsin B and S in the progression of prostate carcinoma. Int J Cancer 95: 51, 2001.
21. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Sloane BF and Gleason DF: Ratio of cathepsin B to stefin A identifies heterogeneity with Gleason histologic scores for human prostate cancer. Prostate 48: 274, 2001.
22. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL and Gleason DF: Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma. Cancer 94: 3141, 2002.
23. International Union Against Cancer: TNM Classification of Malignant Tumors (Sobin LH and Wittekind CH, eds). New York, John Wiley & Sons, 1997, pp170-173.
24. Partin AW, Yoo J, Carter H, Pearson JD, Chan DW, Epstein JI and Walsh PC: The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological staging in men with localized prostate cancer. J Urol 150: 110, 1993.